These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 30181385)

  • 21. [Application of High-throughput Sequencing in Acute Myeloid Leukemia Patients with Positive FLT3-ITD].
    Ma L; Jiang YW; Wang ST; Liu Q; Cong X; Shen J; Cao YY; Cao YT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):381-7. PubMed ID: 27150996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA-based
    Cucchi DGJ; Denys B; Kaspers GJL; Janssen JJWM; Ossenkoppele GJ; de Haas V; Zwaan CM; van den Heuvel-Eibrink MM; Philippé J; Csikós T; Kwidama Z; de Moerloose B; de Bont ESJM; Lissenberg-Witte BI; Zweegman S; Verwer F; Vandepoele K; Schuurhuis GJ; Sonneveld E; Cloos J
    Blood; 2018 May; 131(22):2485-2489. PubMed ID: 29669779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.
    Tecik M; Adan A
    Curr Treat Options Oncol; 2024 Jun; 25(6):719-751. PubMed ID: 38696033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
    Shimada A; Taki T; Koga D; Tabuchi K; Tawa A; Hanada R; Tsuchida M; Horibe K; Tsukimoto I; Adachi S; Kojima S; Hayashi Y
    Int J Hematol; 2012 Oct; 96(4):469-76. PubMed ID: 22915059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
    Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
    Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
    Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
    Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.
    Stirewalt DL; Kopecky KJ; Meshinchi S; Engel JH; Pogosova-Agadjanyan EL; Linsley J; Slovak ML; Willman CL; Radich JP
    Blood; 2006 May; 107(9):3724-6. PubMed ID: 16368883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.
    Buelow DR; Pounds SB; Wang YD; Shi L; Li Y; Finkelstein D; Shurtleff S; Neale G; Inaba H; Ribeiro RC; Palumbo R; Garrison D; Orwick SJ; Blachly JS; Kroll K; Byrd JC; Gruber TA; Rubnitz JE; Baker SD
    Clin Transl Sci; 2019 Nov; 12(6):641-647. PubMed ID: 31350825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of FLT3 internal tandem duplication in pediatric patients with acute myeloid leukemia and its correlation with multidrug resistance].
    Zhao JN; Qiao ZH; Xu LR; Lu QY; Niu XQ; Zhang P; Wang Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):23-6. PubMed ID: 19236740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
    Wang YG; Liu XH; Liang Y; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
    Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
    Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously.
    Mezei ZA; Tornai D; Földesi R; Madar L; Sümegi A; Papp M; Antal-Szalmás P
    J Biotechnol; 2019 Sep; 303():25-29. PubMed ID: 31302157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ITD assembler: an algorithm for internal tandem duplication discovery from short-read sequencing data.
    Rustagi N; Hampton OA; Li J; Xi L; Gibbs RA; Plon SE; Kimmel M; Wheeler DA
    BMC Bioinformatics; 2016 Apr; 17():188. PubMed ID: 27121965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting FLT3 mutations in AML: review of current knowledge and evidence.
    Daver N; Schlenk RF; Russell NH; Levis MJ
    Leukemia; 2019 Feb; 33(2):299-312. PubMed ID: 30651634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
    Zwaan CM; Meshinchi S; Radich JP; Veerman AJ; Huismans DR; Munske L; Podleschny M; Hählen K; Pieters R; Zimmermann M; Reinhardt D; Harbott J; Creutzig U; Kaspers GJ; Griesinger F
    Blood; 2003 Oct; 102(7):2387-94. PubMed ID: 12816873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.